NPM1 and breast carcinoma: Our studies demonstrated that a panel of biomarkers including cathepsin D, CK19, nucleophosmin and peroxiredoxin 2 would be applied as a set of indicators for breast cancer relapse, and they could also represent potential therapeutic targets under sufficient validation.